We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Omega Diagnostics Group Plc | LSE:ODX | London | Ordinary Share | GB00B1VCP282 | ORD 4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.20 | 2.00 | 2.40 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
18/6/2019 18:11 | Looks like for whatever reason this was moved back from the indication I was given from the company back at the end of may. Its seems later than ever so hopefully they are awaiting some good news before publication. Not sure why they will not just publish them to get them out of the way though | upomega | |
18/6/2019 18:07 | They told me the end of June, they then released an RNS to say August. I won’t believe a word they tell me from know on. Poor management.... | barrywhit | |
18/6/2019 14:46 | The company told me recently that they hope to have these out by the end of june | upomega | |
18/6/2019 14:35 | Are you drunk? Results to be announced on the 19th Aug. | likitorma | |
18/6/2019 14:08 | Looks like this dropping again.hopefully we will some director buying after the results which should be any day now.i am hoping that there will also be a positive forward looking statement with clear defined dates as to when we can expect an uplift in revenue.also does anyone know how much money in total has been invested in visitect.my understanding that it was around six million.I would also be interests in so much as to when the capex in this will end | upomega | |
18/6/2019 00:09 | Holiday time in Mexico, California and Germany coming up for Grewal. All expense paid trip by us. | likitorma | |
15/6/2019 17:48 | Naughty.not sure where you stand inyho onions and corduroy trouser's included.is this the beginning or end | upomega | |
15/6/2019 16:37 | Right that's it. Time to use the catapult | upomega | |
15/6/2019 14:23 | I am Norti of the illustrious Raskal family. All my "guests" are kept in the deepest dungeons untl I wish to examine their entrails to verify the efficacy of the Visitect tests. Norti Raskal remains King of the Castle on the inside looking down from his fortress. I Norti Raskal remain leige of the Castle slings and arrows of outrageous fortune deny the alpha and the omega. | raskal | |
15/6/2019 12:09 | Liki is busy enjoying a stay at Norti Raskal's castle. | likitorma | |
13/6/2019 21:31 | Lik What is your opinion on Corduroy trousers and wattles and dorb.lets hope we don't need the baily bridge | upomega | |
13/6/2019 19:03 | Hopefully we will get an rns together with good press coverage.i still can not understand why the burnet institute is not being more proactive with their marketing.After all they may gain further investment together with royalties' if visetect is taken up | upomega | |
13/6/2019 18:45 | I would imagine in the larger factory premises they should be commissioning round about now... | barrywhit | |
13/6/2019 18:32 | The vacancies have been around for a while. Some are duplicated.I wouldn't read too much into it.one question where will visetect be manufactured. | upomega | |
13/6/2019 08:52 | Not sure I like the word Novel... | barrywhit | |
13/6/2019 08:28 | Lots of recruitment going on: Included in the company description: "We have recently launched a novel instrument-free, rapid, lateral flow CD4 test which is used for identifying and managing patients with advanced HIV who are particularly at risk of opportunistic infections." | rivaldo | |
12/6/2019 23:01 | Also lik how do you know this. Great if its true and not as the Donald would say fake news | upomega | |
12/6/2019 22:22 | Lik is that good. Personally looking for food intolerance deals.inmo in the short term any visitect deals will not involve a boost to revenue,but will at a minimum put the company on the world map | upomega | |
12/6/2019 22:07 | Nigeria deal being negotiated as we speak :) | likitorma | |
12/6/2019 21:03 | Archers' to the ready. You naughty raskilion. | upomega | |
11/6/2019 21:53 | Don't be a naughty rascal :). Everyone just waiting now, no buyere or sellers around. | likitorma | |
11/6/2019 17:42 | I am Norti Raskal inside my castle. To moat inhabitant P1nkfish we say you misunderstand the product. Visitect is used to determine CD4 levels in the blood i.e. the threshold for administrating anti vitals. A home test is to see if there is an HIV infection. Treatment is dispensed by a health care professional once HIV has been proven. Norti Raskal is still in the castle waiting for the moat to drain. Only the mud dwellers will survive and prosper. We wait for the siege to be lifted. | raskal | |
07/6/2019 07:27 | The main issue here is the inability of the board to deliver to shareholders. The products are there but the leadership and key decision making is lacking. With their salaries they would have been sweeping the shares if they believed in the company. Yet they are hiding behind "closed periods" apparently. | likitorma | |
07/6/2019 00:10 | upomega, yes, but market not interested and no sign of management acting to sell off the useful bit or go private. | p1nkfish | |
07/6/2019 00:08 | EPRD until 13th Dec 2019 and need Letters of no objection in order to procure, My problem here - risk. Management inability to execute on CD4, investing then pulling back etc. In theory it should do well, practise has been poor. I don't see that having changed so it's still a pure speculation with poor track record as such. Snell at al coughed up more cash. Ok, but what choice did they have? The alternative would have been massive dilution or CD4 go to the wall. Not like they had many choices is it? PDF, worth read, Visiect at bottom and on yellow on all columns - still not there yet - | p1nkfish |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions